NCT03609398View on ClinicalTrials.gov

Phase 2 Safety and Immunogenicity Study of Rift Valley Fever Vaccine

PHASE2RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

October 4, 2018

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2024

Conditions
Rift Valley Fever
Interventions
BIOLOGICAL

RVF Vaccine

1.0 mL dose given SQ in upper arm

Trial Locations (1)

21702

RECRUITING

Special Immunization Program, Division of Medicine, USAMRIID, Fort Deterick

All Listed Sponsors
lead

U.S. Army Medical Research and Development Command

FED